Literature DB >> 20338593

Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells.

Zhao-Xia Wang1, Bin-Bin Lu, Jin-Song Yang, Ke-ming Wang, Wei De.   

Abstract

BACKGROUND: The hepatocyte growth factor receptor c-Met and its ligand hepatocyte growth factor (HGF) have been reported to be involved in cellular motility, growth, and invasion by activating mitogenic signaling pathways. The overexpression of c-Met gene has been found in many malignant cancers, but the roles of c-Met overexpression in SCLC tumors still remain unclear. The aim of the present study was to explore its roles and potential as a therapeutic target for SCLC.
METHODS: Quantitative real-time RT-PCR and immunohistochemistry assays were performed to detect the expression of c-Met mRNA and protein in SCLC tissue or corresponding non-tumor lung tissue samples. Adenovirus-mediated small interfering RNA (siRNA) was employed to down-regulate the expression of c-Met gene in SCLC cell line (NCI-H446). MTT and colony formation assays were performed to detect in vitro proliferation of NCI-H446 cells. In vitro wound-healing and transwell invasion assays were performed to detect in vitro invasion and metastasis of NCI-H446 cells. Finally, in vivo tumorigenicity and metastasis assays were done to analyze in vivo proliferation and metastasis of NCI-H446 cells in a xenograft model.
RESULTS: We showed that the levels of c-Met mRNA expression were significantly higher in SCLC tissue samples (0.97±0.08) than those in corresponding non-tumor lung tissue samples (0.21±0.02; P<0.05). Additionally, the immunostaining of c-Met protein in SCLC tissues was stronger than that in corresponding non-tumor tissues. Adenovirus-mediated siRNA targeting c-Met could significantly down-regulate c-Met expression, and the specific down-regulation of c-Met expression in SCLC cells could strongly inhibit proliferation of SCLC cells both in vitro and in vivo. Moreover, c-Met down-regulation could also reduce invasion capacity in vitro and metastasis capacity in vivo of SCLC cells.
CONCLUSIONS: Taken together, our results indicated that the overexpression of c-Met gene played an important role in the progression and development of SCLC, and adenovirus-mediated siRNA targeting c-Met could potentially be an experimental approach for SCLC gene therapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338593     DOI: 10.1016/j.jss.2009.12.016

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  10 in total

1.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

2.  MiR-144-3p inhibits the proliferation and metastasis of lung cancer A549 cells via targeting HGF.

Authors:  Guiju Fang; Canhui Zhang; Zhixin Liu; Zhiwen Peng; Meiyan Tang; Qing Xue
Journal:  J Cardiothorac Surg       Date:  2022-05-14       Impact factor: 1.522

3.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo.

Authors:  Chandrashekhar D Kamat; Ron B Shmueli; Nick Connis; Charles M Rudin; Jordan J Green; Christine L Hann
Journal:  Mol Cancer Ther       Date:  2013-01-30       Impact factor: 6.261

5.  Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.

Authors:  Hirokazu Taniguchi; Tadaaki Yamada; Shinji Takeuchi; Sachiko Arai; Koji Fukuda; Shuichi Sakamoto; Manabu Kawada; Hiroyuki Yamaguchi; Hiroshi Mukae; Seiji Yano
Journal:  Cancer Sci       Date:  2017-06-08       Impact factor: 6.716

Review 6.  Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Authors:  Ravi Salgia; Isa Mambetsariev; Blake Hewelt; Srisairam Achuthan; Haiqing Li; Valeriy Poroyko; Yingyu Wang; Martin Sattler
Journal:  Oncotarget       Date:  2018-05-25

Review 7.  [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].

Authors:  Yongwen Li; Hongyu Liu; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-08-20

Review 8.  MET and Small-Cell Lung Cancer.

Authors:  Francesco Gelsomino; Giulio Rossi; Marcello Tiseo
Journal:  Cancers (Basel)       Date:  2014-10-13       Impact factor: 6.639

Review 9.  [Advances on Driver Mutations of Small Cell Lung Cancer].

Authors:  Bing Tong; Jing Zhao; Mengzhao Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20

Review 10.  Mechanisms of small cell lung cancer metastasis.

Authors:  Julie Ko; Monte M Winslow; Julien Sage
Journal:  EMBO Mol Med       Date:  2020-12-09       Impact factor: 14.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.